Serum BDNF Role as a Biomarker for Stroke Rehabilitation

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

150 participants

Study Classification

OBSERVATIONAL

Study Start Date

2017-02-01

Study Completion Date

2019-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study aims to develop the quantitative biomarker to establish the individualized strategy in stroke rehabilitation. Brain-derived neurotrophic factor (BDNF) acts on certain neurons of the central nervous system (CNS) helping to support the survival of existing neurons, and encourage the growth and differentiation of new neurons and synapses. BDNF in CNS can be assessed by analysing serum BDNF. The final objective of this study is to demonstrate a role of biomarker of BDNF in stroke rehabilitation to establish the individualized strategy.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Factors Related to Functional Recovery Using Brain Imaging of Stroke Patients

NCT03632070

Stroke

COMPLETED

Effect of Lifestyle Changes on BDNF Level After Stroke

NCT03701815

Stroke

UNKNOWN NA

Correlation Between Clinical Neurological Biomarkers and Rehabilitation Outcome

NCT06805929

Stroke

RECRUITING

Recovery Prediction of Motor Function Using Neuroimaging Techniques in Subacute Stroke Patients

NCT03365596

Stroke

COMPLETED

Establishing a Prognostic Model for Stroke Recovery

NCT05332652

Stroke, Acute

RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Serum BDNF, proBDNF and MMP-9 in all participants will be measured before and after the comprehensive inpatient rehabilitation during subacute stroke phase. At 3 months after stroke onset, serum BDNF, proBDNF and MMP-9 will also be measured.

In addition, motor impairment with Fugl-Meyer assessement will be assessed at same time points with serum analysis.

We will compare potential serum biomarkers with motor impairment in stroke patients

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Stroke Biomarker Rehabilitation BDNF

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Conventional inpatient rehabilitation

comprehensive inpatient rehabilitation for 2 weeks

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* unilateral stroke patients
* admission to the rehabilitation department before 1 month after stroke onset
* mild to severe motor impairment at time of transferring to the rehabilitation department

Exclusion Criteria

* Progressive or unstable stroke
* Pre-existing and active major neurological disease
* Pre-existing and active major psychiatric disease
* Advanced liver, kidney, cardiac, or pulmonary disease
* A terminal medical diagnosis consistent with survival \< 1 year)
* Pregnant or lactating woman

Minimum Eligible Age

19 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No